Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist
- PMID: 3889035
- DOI: 10.1210/jcem-61-1-152
Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist
Abstract
To explore further the relationship of gonadal sex steroids to the rise in somatomedin-C (Sm-C) during puberty, we studied a group of children with true precocious puberty before and after treatment which suppressed sex steroid output. Plasma estradiol and testosterone and serum acid-ethanol-extractable Sm-C were determined by specific RIAs in 7 boys and 12 girls with true precocious puberty before and at regular intervals during treatment with a potent LHRH-agonist (LHRH-A), D-Trp6-Pro9-NEt-LHRH. For comparison, Sm-C and sex steroid concentrations were determined in 266 normal adolescents and 37 normal prepubertal children, 1-9 yr of age. The mean +/- SEM Sm-C levels in normal male individuals peaked at 15 yr (2.46 +/- 0.23 U/ml) and at pubertal (genital) stage III (2.29 +/- 0.19 U/ml), and those in normal females reached their highest concentration at 12-15 yr of age and at pubertal (breast) stage III (2.47 +/- 0.15 U/ml). Sm-C concentrations correlated better with pubertal (genital or breast) stage than with chronological age for both sexes and better with testosterone levels in males than with estradiol levels in females. The mean +/- SEM Sm-C concentrations in both males and females with true precocious puberty were 2.07 +/- 0.16 U/ml before therapy and decreased significantly to 1.52 +/- 0.13 U/ml after 6 months of therapy. The mean Sm-C level of the patients remained significantly elevated for chronological age, but decreased into the normal range for bone age after 6-12 months of therapy. Sm-C correlated significantly with testosterone and estradiol levels, but not with growth rate. Mean nighttime GH secretion decreased significantly after 6 months of LHRH-A therapy. In summary, children with true precocious puberty have Sm-C elevations typical of normal puberty. The decrease in Sm-C levels after suppression of gonadal sex steroid output with LHRH-A is evidence that sex steroids are necessary to induce this elevation in Sm-C concentration. The decrease in GH secretion during LHRH-A therapy suggests that the effect of sex steroids on Sm-C levels during normal puberty is mediated, at least in part, through stimulation of GH secretion.
Similar articles
-
Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty.J Clin Endocrinol Metab. 1988 Jan;66(1):3-9. doi: 10.1210/jcem-66-1-3. J Clin Endocrinol Metab. 1988. PMID: 2961786
-
Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.J Clin Endocrinol Metab. 1985 Jul;61(1):142-51. doi: 10.1210/jcem-61-1-142. J Clin Endocrinol Metab. 1985. PMID: 3923027
-
Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.J Clin Endocrinol Metab. 1986 Apr;62(4):670-7. doi: 10.1210/jcem-62-4-670. J Clin Endocrinol Metab. 1986. PMID: 2936759
-
Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.Endocr Rev. 1986 Feb;7(1):24-33. doi: 10.1210/edrv-7-1-24. Endocr Rev. 1986. PMID: 2937629 Review.
-
[Relation of the secretion of growth hormone (GH), somatomedin C/IGF I (IGF I) and steroids before and after the beginning of puberty in patients of short stature].Pathol Biol (Paris). 1990 Feb;38(2):105-12. Pathol Biol (Paris). 1990. PMID: 2138277 Review. French.
Cited by
-
Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins.Eur J Pediatr. 1988 Apr;147(3):263-9. doi: 10.1007/BF00442692. Eur J Pediatr. 1988. PMID: 3134243
-
GnRH agonists and antagonists. Current clinical status.Drugs. 1988 Jan;35(1):63-82. doi: 10.2165/00003495-198835010-00004. Drugs. 1988. PMID: 3278879 Review.
-
The association between skeletal maturation and adrenal androgen levels in obese children and adolescents.Ann Pediatr Endocrinol Metab. 2017 Jun;22(2):108-114. doi: 10.6065/apem.2017.22.2.108. Epub 2017 Jun 28. Ann Pediatr Endocrinol Metab. 2017. PMID: 28690989 Free PMC article.
-
Serum hormones and physical performance capacity in young boy athletes during a 1-year training period.Eur J Appl Physiol Occup Physiol. 1990;60(1):32-7. doi: 10.1007/BF00572182. Eur J Appl Physiol Occup Physiol. 1990. PMID: 2311591
-
Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty: A Diagnostic Pitfall.Int J Endocrinol. 2010;2010:370692. doi: 10.1155/2010/370692. Epub 2010 Aug 30. Int J Endocrinol. 2010. PMID: 20862389 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical